MustGrow Biologics Corp achieved a net profit of about $300,000 in Q2 2026, a sharp turnaround from a loss of $1.1 million in the same quarter last year, driven by licensing revenue of approximately $1.4 million from its Bayer partnership. TerraSante sales revenue was only $75,000 with a negative gross margin of about $17,000 due to costly air freight from Asia, but year-to-date sales as of August 15 reached roughly $900,000, up 46% compared to all of 2025. Operating expenses normalized at about $900,000 per quarter, and the company ended the quarter with $4.4 million in cash and $5.2 million in working capital. Management expects gross margins to improve to 25-40% as it shifts to ocean freight, and production capacity is projected at CAD15-25 million at nameplate, though the company still faces manufacturing hiccups and periods of being sold out. The next Bayer milestone is not expected until 2027 at the earliest, and regulatory progress for TerraMG in the US and Canada remains slow.
Bayer AG NAMustGrow's Q2 2026 swing to a $300,000 net profit was driven by ~$1.4M in licensing revenue from its Bayer partnership, with the next Bayer milestone not expected until 2027.
OK Rusal MKPAO